Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

AROMASIL 25 mg COMPRIMIDOS RECUBIERTOS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/AROMASIL 25 mg COMPRIMIDOS RECUBIERTOS

Approved

STANDARD

AROMASIL 25 mg COMPRIMIDOS RECUBIERTOS

Pfizer S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: May 8, 2025
Approval ID: 8ddd151ad795c0d3
Company: Pfizer S.L.
Type: Standard

Approval Details

Approval Id: 8ddd151ad795c0d3
Drug Cima Aemps Name: AROMASIL 25 mg COMPRIMIDOS RECUBIERTOS
Register Number: 4400501C
Holder Company Name: Pfizer S.L.
Marketing Company Name: Abacus Medicine A/S
Authorization Date: 2025-05-08
Dosage Form: COMPRIMIDO RECUBIERTO
Dose: 25 mg exemestano
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Pfizer S.L.

Active Ingredients

EXEMESTANO

25 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

May 8, 2025

Approval ID

8ddd151ad795c0d3

Type

Standard

Back to CIMA-AEMPS Approvals